論文

国際誌
2021年8月

Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy.

Anticancer research
  • Kenichi Nakamura
  • Kazunori Kusumoto
  • Yoshinori Ozono
  • Kazuo Kuroki
  • Yunosuke Matsuura
  • Toshihiro Mukuda
  • Toshimasa Ochiai
  • Mai Tsuchimochi
  • Hisayoshi Iwakiri
  • Satoru Hasuike
  • Kazuya Shimoda
  • Kenji Nagata
  • 全て表示

41
8
開始ページ
4127
終了ページ
4131
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/anticanres.15215

BACKGROUND/AIM: Direct-acting antiviral (DAA) therapies for patients with hepatitis C virus (HCV) infection deliver higher cure rates and lower frequencies of adverse events than existing therapies, though DAA treatment costs $45,000-64,000 in Japan. The prognosis of patients who require new long-term care insurance (LTCI) certification is inferior to that of patients who do not. Here, we clarify the factors associated with new LTCI certification in elderly patients with HCV infection who undergo DAA therapy. PATIENTS AND METHODS: We retrospectively surveyed 53 patients aged ≥70 years who were treated with DAAs, and evaluated the factors associated with new LTCI certification. RESULTS: Of 53 patients, 10 required new LTCI certification. Age ≥85 years and a modified Japanese Cardiovascular Health Study index ≥2 were independently associated with new LTCI certification. CONCLUSION: In elderly HCV patients, poor frailty status strongly predicted new LTCI certification after DAA therapy.

リンク情報
DOI
https://doi.org/10.21873/anticanres.15215
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34281883
ID情報
  • DOI : 10.21873/anticanres.15215
  • PubMed ID : 34281883

エクスポート
BibTeX RIS